Wednesday, February 10, 2010, 2:25am EST - Canadian Markets open in 7 hours and 5 minutes.
To create a watchlist or portfolio of shares, Sign-in or Register

Xenoport, Inc. (XNPT)

 On Feb 9: 18.92 USD  Down 0.20 (1.05%)  
MORE ON XNPT
Quotes
HereSummary
Charts
News & Info
Company
Analyst Coverage
Ownership
Financials
XenoPort, Inc. (NasdaqNM:XNPT) Delayed quote dataEdit
After Hours: 19.30 Up 0.38 (2.01%) as of 6:06pm EST on 02/09/10
Last Trade: 18.92 USD
Trade Time: Feb 9
Change: Down 0.20 (1.05%)
Prev Close: 19.12
Open: 19.29
Bid: 18.85 x 100
Ask: 21.61 x 1000
1y Target Est: 31.31
Day's Range: 18.81 - 19.36
52wk Range: 13.36 - 27.37
Volume: 201,690
Avg Vol (3m): 324,492
Market Cap: 574.03M
P/E (ttm): N/A
EPS (ttm): -2.43
Div & Yield: N/A (N/A%)
Xenoport, Inc. (XNPT)
1d  5d  3m  6m  1y  2y  5y 
Free Annual Reports
 Add XNPT to Portfolio   Download Data

HEADLINES
• XenoPort Announces Extension of the Horizant PDUFA Date to February 11, 2010
Business Wire (Tue 4:19pm)
• InPlay: XenoPort announces extension of the Horizant PDUFA date to February 11, 2010
Briefing.com (Tue 4:13pm)
• Glaxo savings plan may hit XenoPort partnership
AP (Thu, Feb 4)
• XenoPort Announces Horizant as Brand Name for XP13512
Business Wire (Thu, Feb 4)
• Biotech Calendar: Key Dates for February
at TheStreet.com (Tue, Feb 2)
• XENOPORT INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exhibits
EDGAR Online (Tue, Jan 19)
• XenoPort to Present at the 28th Annual J.P. Morgan Healthcare Conference
Business Wire (Fri, Jan 8)
• XENOPORT INC Files SEC form 8-K, Other Events
EDGAR Online (Thu, Nov 19)
• Astellas and XenoPort Announce Submission of a New Drug Application in Japan Requesting PMDA Approval of ASP8825/XP13512 for Restless Legs Syndrome
Business Wire (Thu, Nov 19)
• Music to Health-Care Investors' Ears
at Motley Fool (Mon, Nov 16)
More Headlines for XNPT...
ANALYST
EPS Est (next year) (Dec-09) : -2.41
EPS Est (in 2 years) (Dec-10) : -2.29
Avg Rec (current)*: 2.1
PEG Ratio: N/A
* (Strong Buy) 1.0 - 5.0 (Strong Sell)
Analyst Opinion - Estimates

BUSINESS SUMMARY
XenoPort, Inc., a biopharmaceutical company, focuses on developing internally discovered product candidates that utilize the body’s natural nutrient transport mechanisms to enhance the therapeutic benefits of drugs.

Full Company Profile

Add to My Portfolio Add to Portfolio    Email to a Friend Email to a Friend
Get Summary for Another Symbol:
Symbol Lookup
• Latest News • Canadian Indices